Fitbit Inc and Apple Inc. have taken wearable-based health monitoring mainstream and set the stage to link sensors to drug delivery systems or therapy regimens.
“There’s a lot that you can do with a small [device],” Tim Goodnow, president and CEO of the diabetes-focused medtech company Senseonics Holdings Inc told Benzinga. “Not only could it give direct feedback to the patient themselves or the caregiver, the doctors, in regard to any particular status in the moment, it’s just a new revolution of medicine that we’re heading into.”
Senseonics is at the vanguard of health automation. Its first step is commercializing the Eversense Glucose Monitoring System, which recently won FDA approval as the world’s first implantable glucose sensor.